Table 3.

Number of events and unadjusted event rates (per 100 patient years) by hypertension category

OutcomeNo. of Events (Event Rate per 100 patient-years)
White Coat Apparent Treatment-Resistant HypertensionAmbulatory Blood Pressure Monitoring Apparent Treatment-Resistant HypertensionNo Apparent Treatment-Resistant Hypertension
By Ambulatory Blood Pressure Monitoring CriteriaBy Use of >3 Antihypertensive Medications
Composite cardiovascular outcomes8 (4.68)52 (8.19)68 (6.43)90 (2.77)
Kidney outcomes13 (8.74)67 (12.75)65 (6.81)88 (2.97)
Mortality2 (1.04)38 (4.93)54 (4.32)76 (2.18)
  • Ambulatory BP monitoring apparent treatment-resistant hypertension indicates apparent treatment-resistant hypertension by ambulatory BP monitoring criteria or use of more than three antihypertensive medications; white coat apparent treatment-resistant hypertension indicates apparent treatment-resistant hypertension by office BP but not by ambulatory BP monitoring criteria. Composite cardiovascular outcomes are myocardial infarction, stroke, peripheral arterial disease, and heart failure. Kidney outcomes are 50% decrease in eGFR or ESKD defined as renal transplantation or start of long-term renal dialysis.